1.95

22.64% 0.36

Novabay Pharmaceuticals Inc (NBY)

Overview News Price History Discussions Forecast Stock Split

Novabay Pharmaceuticals Inc stock is traded at $1.95, with a volume of 626.37K. It is up +22.64% in the last 24 hours and up +0.00% over the past month. NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Previous Close:

$1.59

Open:

$1.58

24h Volume:

626.37K

Relative Volume:

1.22

Market Cap:

$51.92M

Revenue:

$521.00K

Net Income/Loss:

$-8.53M

P/E Ratio:

-0.7569

EPS:

-2.5762

Net Cash Flow:

$-7.71M

1W Performance:

+0.00%

1M Performance:

+0.00%

6M Performance:

-64.22%

1Y Performance:

-29.41%

1-Day Range:

$1.57

$1.98

1-Week Range:

$1.57

$1.98

52-Week Range:

$1.11

$99.75

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name

Novabay Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

510-899-8800

Address

2000 Powell Street, Suite 1150, Emeryville, CA

Employee

Twitter

@NovaBayPharma

Next Earnings Date

2026-05-21

Latest SEC Filings

NBY's Discussions on Twitter

Compare NBY vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBY Novabay Pharmaceuticals Inc	1.95	51.92M	521.00K	-8.53M	-7.71M	-2.5762
VRTX Vertex Pharmaceuticals Inc	447.54	113.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.78	65.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	835.99	52.14B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.98	40.73B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.48	32.87B	742.00K	-1.37B	-1.07B	-7.0731

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-19	Initiated	Ladenburg Thalmann	Buy
Jul-06-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Reiterated	Laidlaw	Buy
Jun-05-17	Initiated	ROTH Capital	Buy
Mar-27-17	Initiated	Laidlaw	Buy
Feb-06-17	Initiated	Rodman & Renshaw	Buy
Mar-07-16	Downgrade	Maxim Group	Buy → Hold
Dec-14-15	Reiterated	Maxim Group	Buy
Apr-30-15	Resumed	Maxim Group	Buy
Mar-06-13	Initiated	Ascendiant Capital Markets	Strong Buy
Jan-03-08	Initiated	Dawson James	Speculative Buy

View All

Novabay Pharmaceuticals Inc Stock (NBY) Latest News

May 25, 2026

NovaBay Pharmaceuticals (NBY) Surges 22.6%: Key Levels to MonitorExtension Target - thelegaladvocate.com

May 25, 2026

NovaBay Pharmaceuticals (NBY) Jumps 22.6% as Trading Volume SurgesLow Risk Entry Stocks - Newser

May 25, 2026

May 15, 2026

NBY (NovaBay Pharmaceuticals) leadership outlines new clinical and commercial priorities following its latest quarterly earnings release.Dividend Increase - newser.com

May 01, 2026

Apr 30, 2026

Stablecoin Development Corp (Formerly NovaBay Pharmaceuticals) 2025 Annual 10-K/A Filing: Stock, Warrants, and Equity Transactions Overview - Minichart

Apr 30, 2026

Apr 29, 2026

Massive non-cash warrant error drives 2025 restatement at Stablecoin (NBY) - Stock Titan

Apr 29, 2026

Apr 28, 2026

NovaBay Pharmaceuticals to rebrand as Stablecoin Development Corporation - MSN

Apr 28, 2026

Apr 27, 2026

NovaBay rebrands to Stablecoin Development Corp in full crypto pivot—pharma company's stock climbs 19% - MSN

Apr 27, 2026

Apr 25, 2026

NovaBay enters into $6M securities purchase agreement with investor David Lazar - MSN

Apr 25, 2026

Apr 23, 2026

SDEV Stock Price, Quote & Chart | STABLECOIN DEVELOPMENT CORP (NYSEARCA:SDEV) - ChartMill

Apr 23, 2026

Apr 21, 2026

Director at Stablecoin Development Corp (SDEV) receives 140,000 RSU equity grant - Stock Titan

Apr 21, 2026

Apr 18, 2026

Is NovaBay Pharmaceuticals (NBY) stock a smart investment (Slight Rise) 2026-04-18Trending Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Apr 15, 2026

Tether backs Stablecoin Development Corporation’s $134 million private placement used to acquire SKY tokens - The Block

Apr 15, 2026

Tether says participated in a $134 million financing round for stablecoin development corporation - marketscreener.com

Apr 15, 2026

Apr 13, 2026

NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update - ADVFN

Apr 13, 2026

Aug Drivers: Can NovaBay Pharmaceuticals Inc sustain its profitabilityWeekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn

Apr 13, 2026

What accelerates growth of NovaBay Pharmaceuticals (NBY) Stock | Price at $1.95, Up 22.64%Island Reversal - thelegaladvocate.com

Apr 13, 2026

Apr 12, 2026